HomeBUSINESS
BUSINESS

Nippon Shinyaku Preparing for Clinical Studies of 5 Oligonucleotide Drugs to Cover 50% of DMD Patients: Pres.
(Nov.8.2018)

Nippon Shinyaku President Shigenobu Maekawa
Nippon Shinyaku is preparing to conduct global clinical studies of around five oligonucleotide therapeutics for Duchenne muscular dystrophy (DMD) that possess exon-skipping action, President Shigenobu Maekawa revealed at an earning conference on November 6 ...
(LOG IN FOR FULL STORY)